CG Therapeutics, Inc. is a biotechnology company founded in 2005 in Seattle, Washington, to bring effective new cancer therapeutics to market. The company's products will combat hCG, a powerful hormone secreted by cancer cells to promote their growth and spread.
The first of these products, CG201, is a cancer vaccine that is distinctly different from other cancer vaccines. Unlike the majority of cancer vaccine candidates, CG201 stimulates a patient's immune system to produce antibodies that create anti-tumor effects comparable to the widely used monoclonal antibody products Avastin®, Herceptin®, and Erbitux®.
CGT is heir to twenty years of previous development of anti-hCG vaccines, including $30 million of prior investment by government agencies, universities, and corporations. The company's lead product, CG201, is ready to enter late-stage clinical testing. The vaccine has an excellent safety profile and appeared to extend cancer patient's survival in previous Phase 2 clinical trials.
